ITM to Present at the 43rd Annual J.P. Morgan Healthcare Conference
December 13, 2024 05:00 ET
|
ITM Isotope Technologies Munich SE
Garching / Munich, Germany, December 13, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that its Chief Executive Officer, Dr. Andrew...
ITM to Participate in Upcoming Investor Conferences
November 11, 2024 05:00 ET
|
ITM Isotope Technologies Munich SE
Garching / Munich, November 11, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced its participation in two upcoming industry investor...
ITM, TUM und das TUM Universitätsklinikum unterzeichnen eine neue Rahmenvereinbarung zur Entwicklung innovativer radiopharmazeutischer Krebstherapien
October 24, 2024 05:00 ET
|
ITM Isotope Technologies Munich SE
Neufahrn / Garching / München, 24. Oktober 2024 – ITM Isotope Technologies Munich SE (ITM), ein führendes radiopharmazeutisches Unternehmen, die Technische Universität München (TUM) und das TUM...
ITM, TUM, and TUM University Hospital Sign New Framework Agreement to Advance Innovative Radiopharmaceutical Cancer Treatments
October 24, 2024 05:00 ET
|
ITM Isotope Technologies Munich SE
Neufahrn / Garching / Munich, Germany, October 24, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, the Technical University of Munich (TUM) and the TUM...
ITM and NTP Strengthen Global Radioisotope Production Capacities by Renewing their Technology License Agreement and Signing a Manufacturing and Supply Agreement for n.c.a. Lutetium-177
October 18, 2024 05:00 ET
|
ITM Isotope Technologies Munich SE
Extension of 2012 agreement grants NTP the rights to manufacture and distribute non-carrier-added Lutetium-177 (n.c.a. 177Lu)Companies enter into an additional manufacturing and supply...
ITM to Present at Upcoming Radiopharmaceutical Investor Conferences in New York City
September 19, 2024 05:22 ET
|
ITM Isotope Technologies Munich SE
Garching / Munich, September 19, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced its participation in two upcoming industry...
ITM Obtains Exclusive Worldwide License from Debiopharm for CA IX-Targeted Peptide-based Radiopharmaceutical Programs Targeting Solid Tumors
September 12, 2024 05:00 ET
|
ITM Isotope Technologies Munich SE
ITM gains exclusive global development and commercialization rights to Debiopharm’s first-in-class, peptide-based theranostic pair which combines therapeutic compound, Debio 0228 ([177Lu]Lu-DPI-4452)...
ITM ernennt Dr. Andrew Cavey zum CEO, um das weitere Wachstum des Unternehmens voranzutreiben
June 20, 2024 05:00 ET
|
ITM Isotope Technologies Munich SE
Dr. Cavey verfügt über langjährige Berufserfahrung in der radiopharmazeutischen Industrie und wird die Weiterentwicklung von ITMs Pipeline und das Unternehmenswachstum maßgeblich unterstützen....
ITM Appoints Dr. Andrew Cavey as CEO to Lead Organization in its Next Stage of Growth
June 20, 2024 05:00 ET
|
ITM Isotope Technologies Munich SE
With a significant track record of success in the radiopharmaceutical industry, Dr. Cavey will help accelerate ITM’s pipeline and business growth Garching /...
ITM Raises €188m to Enhance Radiopharmaceutical Pipeline and to Strengthen Leading Position in Medical Radioisotope Manufacturing
June 06, 2024 05:00 ET
|
ITM Isotope Technologies Munich SE
Proceeds to support development of ITM’s targeted radiopharmaceutical pipeline and preparations for potential market launch of phase III lead candidate, ITM-11, as it nears clinical read-out Funds...